Micafungin Accord

Micafungin, the active ingredient in Micafungin Accord, is an echinocandin presented as an injectable solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis and is used for prophylaxis of fungal infections in hematopoietic stem cell transplantation. It is indicated for patients with compromised immune systems who are at high risk of systemic fungal infections.

GNH USA supplies Micafungin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Micafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis, and it is used for the following approved indications: - Invasive candidiasis: treatment of bloodstream and deep‑tissue infections caused by Candida species. - Esophageal candidiasis: eradication of Candida infection of the esophagus in immunocompromised patients. - Prophylaxis of fungal infections in hematopoietic stem cell transplantation: prevention of invasive fungal disease during the transplant conditioning period.

Micafungin may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Infusion‑related reactions (flushing, erythema, or chills). - Nausea or vomiting. - Elevated liver enzymes (ALT, AST).

Serious or Rare Side Effects: - Severe hepatic injury or liver failure. - Anaphylactic or severe hypersensitivity reactions, including Stevens‑Johnson syndrome. - Severe hypotension or shock during infusion.

When using Micafungin, consider the following safety measures: - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: perform baseline and periodic liver function tests. - Concomitant azole antifungals: assess for additive hepatotoxicity. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Use in pediatric patients: safety and efficacy have not been fully established. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines; monitor patients accordingly.

Major Interactions (Avoid): - Cytochrome P450 inducers (e.g., rifampin): may markedly reduce micafungin exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase micafungin plasma concentrations.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may require liver enzyme monitoring. - Immunosuppressants (e.g., tacrolimus, cyclosporine): monitor drug levels for potential increase. - Warfarin: observe INR closely for possible anticoagulant effect changes.